OncoMatch/Clinical Trials/NCT06332755
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
Is NCT06332755 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Phase 1a: LB-LR1109 and Phase 1b: LB-LR1109 and Atezolizumab for non-small cell lung cancer(nsclc).
Treatment: Phase 1a: LB-LR1109 · Phase 1b: LB-LR1109 and Atezolizumab — This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and/or metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as combination therapy with atezolizumab in participants with advanced and/or metastatic NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Urothelial Carcinoma
Melanoma
Disease stage
Required: Stage IV
Metastatic disease required
advanced or metastatic solid tumors with measurable or non-measurable disease as determined by RECIST v1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: approved standard therapies — metastatic or advanced
Participants who have metastatic disease which has progressed during or after approved standard therapies or are intolerant to approved therapies, or for which the participant refuses or is ineligible for standard therapy
Cannot have received: LILRB or immunoglobulin-like transcript pathway inhibitor
Has received prior therapy targeting LILRB or immunoglobulin-like transcript pathway
Cannot have received: atezolizumab (atezolizumab)
Participants who were previously exposed to atezolizumab
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Participants with adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEXT Oncology · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify